Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Apple Turns 50: From Garage Startup to AI Crossroads 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
PORT WASHINGTON, N.Y., Sept. 05, 2017 -- ACETO Corporation (NASDAQ:ACET), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Sal Guccione, President and CEO, is scheduled to participate in a fireside chat at the Morgan Stanley 15th Annual Global Healthcare Conference on Tuesday, September 12, 2017 at 4:40 PM ET.
A webcast of the presentation will be available under Events and Presentations in the investor relations section of the company’s website at www.aceto.com.
ABOUT ACETO
ACETO Corporation, incorporated in 1947 and with offices and operations in 10 countries, is engaged in the development, marketing, sale and distribution of Human Health products (finished dosage form generics and nutraceuticals), Pharmaceutical Ingredients (pharmaceutical intermediates and active pharmaceutical ingredients) and Performance Chemicals (specialty chemicals and agricultural protection products).
Investor Relations Contact LHA Jody Burfening [email protected] (212) 838-3777
